The Th17 Master Regulator RORC2 as a New Target for HIV Immune Therapy and Cure Strategy

Th17 主调节因子 RORC2 作为 HIV 免疫治疗和治愈策略的新靶点

• 批准号: 437899
• 负责人: Ancuta Petronela
• 金额: $ 7.29万
• 依托单位: Centre hospitalier de l'Universit de Montral (CHUM)
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2020
• 资助国家: 加拿大
• 起止时间: 2020-10-01 至 2021-10-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=437899&lang=en
• 关键词: Confocal Microscopy; Crispr Cas9; Hiv Transcription; Hiv-1; Human Th17 Cells; Humanized Mice; Image Stream; Rna Sequencing; Rorc2 Reverse Agonists; Viral Reservoir Reactivation And Purging

Combined antiretroviral therapies (ART) are highly efficient at suppressing HIV replication, therefore improving the life quality of people living with HIV. However, ART does not eliminate HIV and if treatment is interrupted, the virus comes back quickly.

联合抗逆转录病毒疗法（ART）在抑制艾滋病毒复制方面非常有效，从而提高了艾滋病毒感染者的生活质量。然而，抗逆转录病毒疗法并不能消除艾滋病毒，如果治疗中断，病毒很快就会卷土重来。